UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date
of Report (Date of earliest event reported):
|
June 18, 2009
|
|
 NIKE,
Inc.
|
||
|
(Exact
name of registrant as specified in charter)
|
||
|
OREGON
|
1-10635
|
93-0584541
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
ONE
BOWERMAN DRIVE
BEAVERTON,
OR
|
97005-6453
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
|
Registrant’s
telephone number, including area code:
|
(503)671-6453
|
|
|
NO
CHANGE
|
||
|
(Former
name or former address, if changed since last
report.)
|
||
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Effective
June 18, 2009, the NIKE, Inc. (the "Company") Board of Directors appointed Dr.
John C. Lechleiter to serve as a Director of the Company.
John C.
Lechleiter, Ph.D, 55, is chairman of the board, president, and chief executive
officer of Eli Lilly and Company ("Lilly"). Dr. Lechleiter joined Lilly in 1979
as a senior organic chemist in the process research and development division,
and has held management positions in England and the U.S. He was named vice
president of pharmaceutical product development in 1993 and vice president of
regulatory affairs in 1994. In 1996, he was named vice president for development
and regulatory affairs. Dr. Lechleiter became senior vice president of
pharmaceutical products in 1998, and executive vice president of pharmaceutical
products and corporate development in 2001. He was named executive vice
president of pharmaceutical operations in 2004. Dr. Lechleiter was appointed
president and chief operating officer of Lilly in 2005, when he also joined
Lilly's board of directors. He was named president and chief executive officer
in April 2008 and became chairman on January 1, 2009.
There was
no arrangement or understanding pursuant to which Dr. Lechleiter was elected as
a director, and there are no related party transactions between the Company and
Dr. Lechleiter. Dr. Lechleiter will serve on the Company's
Compensation Committee and the Corporate Responsibility Committee.
The
Company issued a press release on June 18, 2009 announcing the appointment of
Dr. Lechleiter. The press release is attached hereto as Exhibit
99.1.
Item
9.01 Financial Statements and Exhibits
|
(d)
|
Exhibits
|
The
following exhibits are being furnished with this Current Report on Form
8-K:
Exhibit
99.1 Press
Release dated June 18, 2009.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| NIKE, Inc. | |||
|
Date:
June 22, 2008
|
By:
|
/s/ Donald W. Blair | |
| Name: Donald W. Blair | |||
| Title: Chief Financial Officer | |||